EUVIMEDEUVIMED entdecken
Crossref

Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor

Jeffrey W Johannes iD, Amber Y S Balazs iD, Derek Barratt, Michal Bista, Matthew D Chuba, Sabina Cosulich, Susan E Critchlow, Sébastien L Degorce, Paolo Di Fruscia iD, Scott D Edmondson iD, Kevin J Embrey, Stephen Fawell und 30 weitere

Journal of Medicinal Chemistry · 26.12.2024 · 67 (24) · 21717-21728

DOI: 10.1021/acs.jmedchem.4c01725 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.12.2024. Verfasst von Jeffrey W Johannes und 41 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States. Hauptthemen laut MEDLINE: Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARP inhibitors have attracted considerable interest in drug discovery due to the clinical success of first-generation agents such as olaparib, niraparib, rucaparib, and talazoparib. Their success lies in their ability to trap PARP to DNA; however, first-generation PARP inhibitors were not strictly optimized for trapping nor for selectivity among the PARP enzyme family. Previously we described the discovery of the second-generation PARP inhibitor AZD5305, a selective PARP1-DNA trapper. AZD5305 maintained the antitumor efficacy of first-generation PARP inhibitors while exhibiting lower hematological toxicity. Recently, there has been interest in central nervous system (CNS)-penetrant PARP inhibitors for CNS malignancies and other neurological conditions; however, AZD5305 is not CNS penetrant. Herein we describe the discovery and optimization of a series of CNS-penetrant, PARP1-selective inhibitors and PARP1-DNA trappers, culminating in the discovery of AZD9574, a compound that maintains the PARP1 selectivity of AZD5305 with improved permeability, reduced efflux, and increased CNS penetration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsAnimalsDogsHumansMaleMiceRatsBlood-Brain BarrierCentral Nervous SystemDrug DiscoveryPiperazinesPyridinesStructure-Activity RelationshipNaphthyridines

Substanzen

PiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPyridinesPARP1 protein, humanAZD5305Naphthyridines

Autor:innen und Institutionen

  • Chemistry, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • Oncology Projects, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • Bioscience, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • New Modalities & Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K.
  • Oncology Discovery, Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.

ORCID-Profile: Jeffrey W Johannes, Amber Y S Balazs, Paolo Di Fruscia, Scott D Edmondson, Avipsa Ghosh, Sonja J Gill, Tom D Heightman, Carrie J B Larner, Andy Pike, Marianne Schimpl, Andrew X Zhang

Zitieren

APA

Johannes, J. W., Balazs, A. Y. S., Barratt, D., Bista, M., Chuba, M. D., Cosulich, S., Critchlow, S. E., Degorce, S. L., Di Fruscia, P., Edmondson, S. D., Embrey, K. J., Fawell, S., Ghosh, A., Gill, S. J., Gunnarsson, A., Hande, S. M., Heightman, T. D., Hemsley, P., Illuzzi, G., …, & Zheng, X. (2024). Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor. Journal of Medicinal Chemistry, 67(24), 21717-21728. https://doi.org/10.1021/acs.jmedchem.4c01725

Vancouver

Johannes JW, Balazs AYS, Barratt D, Bista M, Chuba MD, Cosulich S, et al. Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor. Journal of Medicinal Chemistry. 2024;67(24):21717-21728. doi:10.1021/acs.jmedchem.4c01725

BibTeX
@article{Johannes2024,
  author = {Johannes, Jeffrey W and Balazs, Amber Y S and Barratt, Derek and Bista, Michal and Chuba, Matthew D and Cosulich, Sabina and Critchlow, Susan E and Degorce, Sébastien L and Di Fruscia, Paolo and Edmondson, Scott D and Embrey, Kevin J and Fawell, Stephen and Ghosh, Avipsa and Gill, Sonja J and Gunnarsson, Anders and Hande, Sudhir M and Heightman, Tom D and Hemsley, Paul and Illuzzi, Giuditta and Lane, Jordan and Larner, Carrie J B and Leo, Elisabetta and Liu, Lina and Madin, Andrew and McWilliams, Lisa and O'Connor, Mark J and Orme, Jonathan P and Pachl, Fiona and Packer, Martin J and Pei, Xiaohui and Pike, Andy and Schimpl, Marianne and She, Hongyao and Staniszewska, Anna D and Talbot, Verity and Underwood, Elizabeth and Varnes, Jeffrey G and Xue, Lin and Yao, Tieguang and Zhang, Ke and Zhang, Andrew X and Zheng, Xiaolan},
  title = {Discovery of 6-Fluoro-5-4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {24},
  pages = {21717--21728},
  doi = {10.1021/acs.jmedchem.4c01725}
}
Kostenlos starten →